High-Dose Interleukin-2 Effective in mRCC Pre-Treated with VEGF-Targeted Therapies (VIDEO)

European Society for Medical Oncology

Caption

High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pre-treated with VEGF-targeted agents, reveals research presented today at the ESMO Symposium on Immuno-Oncology in Geneva, Switzerland.

Credit

ESMO - European Society for Medical Oncology

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.